746 Critical Quality Attribute Monitoring and Control in Pharmaceutical Manufacturing III


Description:
Developing robust pharmaceutical production processes to ensure patient safety and drug efficacy is dependent on the sound understanding and control of the drug substance and drug product quality attributes relevant for clinical performance and drug product manufacture. This understanding is then translated into the design of the manufacturing process and a relevant monitoring and control system to ensure that quality attributes within the desired ranges are consistently obtained. This session covers both drug substance and drug product critical quality attribute identification, characterization, and monitoring systems for quality and manufacturing process control. Authors are encouraged to highlight clinically relevant specifications for pharmaceutical products and innovative control strategies for drug substance and drug product manufacturing.

Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum
Co-Sponsor(s):
Product Design (12G), Pharmaceuticals (15B)


Chair:
Huiquan Wu
Chemical Engineer
FDA/CDER
OPQ/OPF
LS64 Room 1080
Silver Spring, MD
20993
Phone Number: 3017960022
Fax Number: 301-796-9816
Email: huiquan.wu@fda.hhs.gov

Co-Chair:
Otute Akiti
Senior Director
Relypsa, Inc
Drug Substance Manufacturing & Development
Redwood City, CA
Phone Number: 650.421.9511
Fax Number: 650.421.9711
Email: oakiti@relypsa.com


Papers:
Application of Radiometric Sensor for Inline Mass Flow Rate Monitoring and Control of a Continuous Tablet Manufacturing Line
Sudarshan Ganesh, Purdue University; Qinglin Su, Purdue University; Zoltan K. Nagy, Purdue University; G. V. Reklaitis, Purdue University
Water Proton NMR for Noninvasive Chemical and Pharmaceutical Analysis
Bruce Yu, University of Maryland; Marc Taraban, University of Maryland; Yue Feng, University of Maryland; Katharine Briggs, University of Maryland
Monitoring the Whole Blending End-Point of an-Gong-Niu-Huang Wan Using the QbD Concept
Xiaona Liu, Binzhou Medical University; Qiusheng Zheng, Binzhou Medical University; Xiaoqing Che, Bohai Pharmaceutical Group Co., Ltd.; Zhisheng Wu, Beijing University of Chinese Medicine; Yanjiang Qiao, Beijing University of Chinese Medicine
Steady-State Data Reconciliation of a Direct Compression Tableting Line
Mariana Moreno, Purdue University; Jianfeng Liu, Purdue University; Sudarshan Ganesh, Purdue University; Qinglin Su, Purdue University; Nima Yazdanpanah, U.S. Food and Drug Administration; Thomas O'Connor, U.S. Food and Drug Administration; Carl Laird, Purdue University; Zoltan K. Nagy, Purdue University; Gintaras Reklaitis, Purdue University
Considerations for Control of Manufacturing Processes for Transdermal Systems – FDA Perspective
James Norman, FDA/CDER/OPQ/OPF; Yubing Tang, FDA/CDER/OPQ/OPF; Sharmista Chatterjee, FDA/CDER/OPQ/OPF
Abstract Submissions Closed